Home / Business and Economy / Keros Therapeutics Nets $20M Milestone from Takeda
Keros Therapeutics Nets $20M Milestone from Takeda
15 Aug
Summary
- Keros Therapeutics received a $20 million milestone payment from Takeda.
- The payment is for the Phase 3 elritercept trial in myelodysplastic syndromes.
- Keros plans to distribute 25% of this milestone directly to shareholders.
On July 30, 2026, Keros Therapeutics, Inc. announced it triggered a $20 million development milestone payment from its global partner, Takeda Pharmaceutical Company Limited. This payout is in recognition of the first patient being dosed in the Phase 3 ELRiSE MDS clinical trial, which is evaluating elritercept for anemia associated with myelodysplastic syndromes.
Under their licensing agreement, Keros had already received a $200 million upfront payment in February 2025 and remains eligible for substantial future milestones and royalties. Keros Therapeutics plans to distribute 25% of the net cash proceeds from this $20 million milestone directly to its shareholders.
In contrast, Keros's Q2 2026 financial results showed $0 in revenue, with a net loss of $28.7 million. However, its cash reserves of $257.6 million provide a runway into the first half of 2028, and development costs have decreased significantly due to the transition of elritercept expenses to Takeda.
Despite Keros's financial standing as a clinical-stage company, its strategy is effective. The bull case for Keros hinges on potential pipeline success and non-dilutive capital, while the bear case acknowledges its reliance on a single lead candidate and Takeda's global commercial execution.
